Bio News
LigaChem Biosciences secured the exclusive development rights to NextCure’s B7H4-ADC, “LNCB74,” for at least 54.1 billion won. The company said the total value of the agreement exceeds 10% of its equity capital at the end of 2025. Following NextCure’s reverse merger, LigaChem Biosciences plans to pursue independent development and out-licensing to third parties.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
